AGAMREE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AGAMREE (AGAMREE).
Synthetic glucocorticoid receptor agonist; modulates transcription via glucocorticoid response elements, suppressing inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) and immune cell activity.
| Metabolism | Hepatic via CYP3A4 |
| Excretion | Primarily hepatic metabolism; <10% excreted unchanged in urine. Fecal excretion accounts for approximately 30% of metabolites. Renal excretion of metabolites accounts for about 60%. |
| Half-life | Terminal elimination half-life is approximately 2.5-3 hours in adults. The half-life may be prolonged in patients with hepatic impairment. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Volume of distribution is approximately 1.4 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 60-70%. |
| Onset of Action | Oral: Onset of clinical effect is typically within 1-2 hours; peak plasma concentrations are reached within 1-2 hours. |
| Duration of Action | Duration of action is 12-24 hours based on clinical response and dose. The drug is administered once daily due to its long-acting anti-inflammatory effect. |
| Molecular Weight | 360.44 |
Initial dose: 600 mg (6 tablets of 100 mg or 3 tablets of 200 mg) orally once daily for 4 weeks, then 400 mg orally once daily for weeks 5-8; total treatment duration 8 weeks.
| Dosage form | SUSPENSION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment or ESRD; use caution. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment; avoid use. |
| Pediatric use | Approved for patients aged 2 years and older with Duchenne muscular dystrophy. Dosing based on weight: if body weight ≥20 kg, same as adult (600 mg once daily for 4 weeks, then 400 mg once daily for 4 weeks); if body weight <20 kg, 300 mg once daily for 4 weeks, then 200 mg once daily for 4 weeks. |
| Geriatric use | No specific dose adjustments. Limited data in patients >65 years; use with caution due to potential increased risk of adverse effects (e.g., glucocorticoid-related). |
| 1st trimester | Use only if clearly needed; limited human data, animal studies show increased risk of cleft palate at high doses. |
| 2nd trimester | May use if benefits outweigh risks; monitor fetal growth; potential for adrenal suppression in neonate. |
| 3rd trimester | Avoid prolonged use; risk of neonatal adrenal suppression and growth restriction; use lowest effective dose. |
Clinical note
Comprehensive clinical and safety monograph for AGAMREE (AGAMREE).
| Placental transfer | Prednisolone crosses the placenta; approximately 10% of maternal concentration reaches fetal circulation. The placenta has 11β-HSD2 activity which inactivates prednisolone to prednisone, limiting fetal exposure. |
| Breastfeeding | Prednisolone (active metabolite) is excreted into breast milk in low amounts. With maternal doses up to 40 mg/day, infant exposure is minimal. However, monitor infant for adrenal suppression if mother is on long-term high-dose therapy. Use with caution, ideally after nursing to minimize exposure. |
■ FDA Black Box Warning
None
| Common Effects | Itching Chest pain Headache Hypertrichosis excessive hair growth Rash Dermatitis Hypersensitivity Weight gain Fluid retention Tachycardia |
| Serious Effects |
Systemic fungal infectionsHypersensitivity to prednisolone or any componentAdministration of live or live-attenuated vaccines
| Precautions | Immunosuppression and increased infection risk, Hypothalamic-pituitary-adrenal axis suppression, Cushing's syndrome with prolonged use, Growth retardation in children, Osteoporosis, Cataracts and glaucoma, Gastrointestinal perforation risk |
| Food/Dietary | Grapefruit and grapefruit juice may increase vamorolone levels. Avoid concurrent consumption. Take with food to minimize gastric upset. |
Loading safety data…
| Lactation Rating | L2 (Safer; based on limited data, risk unlikely) |
| Teratogenic Risk | AGAMREE (vamorolone) is a corticosteroid; animal studies show fetal harm (cleft palate, growth retardation) at clinically relevant doses. First trimester exposure carries risk of orofacial clefts (odds ratio ~1.3-2.0). Second/third trimester exposure associated with increased risk of preterm birth, low birth weight, and neonatal adrenal suppression. Avoid use in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Fetal monitoring: serial growth scans (for intrauterine growth restriction) and assessment for preterm labor. Newborn: monitor for adrenal insufficiency (hypoglycemia, hypotension, electrolyte disturbances). |
| Fertility Effects | Corticosteroids may impair fertility in both males and females via hypothalamic-pituitary-adrenal axis suppression. In males, potential for reduced sperm count; in females, menstrual irregularities and ovulatory dysfunction. Effects are dose-dependent and reversible upon dose reduction or discontinuation. |
| Clinical Pearls | AGAMREE (vamorolone) is a dissociative steroid with reduced glucocorticoid receptor-mediated side effects. Monitor for adrenal suppression during taper; do not abruptly discontinue. May cause transient growth velocity reduction in children. Baseline and periodic bone density assessment recommended. Avoid live vaccines during therapy. Dose adjustments needed for hepatic impairment. |
| Patient Advice | Take with food to reduce gastrointestinal irritation. · Do not stop taking suddenly; taper under medical supervision. · Report any signs of infection, mood changes, or vision problems. · Avoid grapefruit juice during treatment. · Carry a steroid card and inform other healthcare providers of use. · Children's growth should be monitored regularly. |